申请人:Janssen Pharmaceutica N.V.
公开号:US05254556A1
公开(公告)日:1993-10-19
The invention relates to C.sub.2-20 alkanoic acid esters of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6, 7,8,9-tetrahydro-9-hydroxy-2 -methyl-4H-pyrido[1,2-a]pyrimidin-4-one, pharmaceutically acceptable acid addition salts thereof, and enantiomeric forms thereof, which are useful in the treatment of warm-blooded animals suffering from psychotic diseases.
本发明涉及C.sub.2-20烷基酸酯,其为3-[2-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶[1,2-a]嘧啶-4-酮的药物可接受的酸加盐及其对映体形式,其用于治疗患有精神疾病的温血动物。